The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
February 19, 2024
View Complete Issue         Table of Contents 2019 
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
February 19, 2024 (Issue: 1696)
Fruquintinib (Fruzaqla – Takeda), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
Article code: 1696f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.